Abstract: This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described herm partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described herm relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.

Abstract: Described herein is a polyurethane foam prepared with certain polytetrahydrofurans and optional polyether polyols. The polyurethane foam is characterized by low hardness increase at low temperature as compared with conventional polyurethane foam, and is suitable for use in products which can be exposed to low temperature such as snow boots.

Abstract: Enediyne compounds having a structure according to formula (I), where R1, R2, R3, R4, R5, R6, R7 and X are defined herein.

Abstract: Enediyne compounds having a structure according to formula (I), where R1, R2, R3, R4, R5, R6, R7 and X are defined herein.

Abstract: Enediyne compounds having a structure according to formula (I), where R1, R2, R3, R4, R5, R6, R7 and X are defined herein.

Abstract: The present invention relates to the cloning and sequence of a biosynthetic gene cluster from Streptomyces platensis that produces platensimycin and platencin. Also provided are engineered micro-organisms for the production of these compounds, and analogs thereto, as well as methods of screening for compounds with anti-bacterial activity.

Abstract: The present invention relates to tautomycetin (TTN) and analogs thereof. Also provided are methods of using TTN and analogs thereof in the treatment of various diseases relating to SHP2 function.

Abstract: The present invention relates to the biosynthetic gene cluster for tautomycetin (TTN) produces tautomycetin. Also provided are engineered micro-organisms for the production of TTN and analogs thereof, as well as methods of screening for compounds for activity.

Abstract: The present invention relates to the biosynthetic gene cluster for tautomycetin (TTN) produces tautomycetin. Also provided are engineered micro-organisms for the production of TTN and analogs thereof, as well as methods of screening for compounds for activity.

Abstract: The present invention relates to tautomycetin (TTN) and analogs thereof. Also provided are methods of using TTN and analogs thereof in the treatment of various diseases relating to SHP2 function.

Abstract: Provided herein is a method of targeting stem cells to a specific region of the central nervous system of an individual in need of such treatment, comprising the steps of administering stem cells containing a superparamagnetic nanoparticles to said individual; and applying an external source of a magnetic field to the exterior of said individual's brain so as to advance and maneuver said stem cells. Also provided is a composition for targeting cells to a specific region of the central nervous system of an individual in need of such treatment, comprising stem cells containing a superparamagnetic nanoparticles.

Abstract: The present invention relates to the cloning and sequence of a biosynthetic gene cluster from Streptomyces platensis that produces platensimycin and platencin. Also provided are engineered micro-organisms for the production of these compounds, and analogs thereto, as well as methods of screening for compounds with anti-bacterial activity.

Abstract: Genetic and biochemical characterization of the leinamycin biosynthesis gene cluster from Streptomyces atroolivaceus S-140 revealed two PKS genes, lnmI and lnmJ, that encode six PKS modules, none of which contains a cognate AT domain. The AT activity is provided in trans by a discrete protein, LnmG, which loads the malonyl coenzyme A extender unit onto the ACP domains of all six PKS modules. This finding provides a basis for methods of engineering modular polyketide synthases and polyketide synthase/nonribosomal peptide synthetases.

Abstract: The present invention provides methods of modifying a biological molecule by C—O bond formation utilizing a type II polyketide synthase (PKS) system from the nonactin biosynthesis gene cluster. The type II PKS responsible for biosynthesis of the macrotetralide nonactin includes polypeptides encoded by the nonJK genes. The NonJ and NonK polypeptides have been identified by the inventors as ketoacyl synthases capable of directly catalyzing C—O bond formation between substrate molecules. This invention increases the scope and diversity of chemical syntheses available for drug design and combinatorial biosynthesis.

Abstract: Genetic and biochemical characterization of the leinamycin biosynthesis gene cluster from Streptomyces atroolivaceus S-140 revealed two PKS genes, lnmI and lnmJ, that encode six PKS modules, none of which contains a cognate AT domain. The AT activity is provided in trans by a discrete protein, LnmG, which loads the malonyl coenzyme A extender unit onto the ACP domains of all six PKS modules. This finding provides a basis for methods of engineering modular polyketide synthases and polyketide synthase/nonribosomal peptide synthetases.

Abstract: The present invention relates to TG-25 and/or analogs thereof and their use of TG-25 in the treatment of cancer. TG-25 inhibits the growth of prostate cells by inhibiting DNA synthesis, more particularly by DNA cleavage.

Abstract: Genetic and biochemical characterization of the leinamycin biosynthesis gene cluster from Streptomyces atroolivaceus S-140 revealed two PKS genes, lnmI and lnmJ, that encode six PKS modules, none of which contains a cognate AT domain. The AT activity is provided in trans by a discrete protein, LnmG, which loads the malonyl coenzyme A extender unit onto the ACP domains of all six PKS modules. This finding provides a basis for methods of engineering modular polyketide synthases and polyketide synthase/nonribosomal peptide synthetases.

Abstract: The present invention provides for fusion proteins that act as targeted drug carries. The proteins are derived from molecules that possess natural drug-binding capabilities that are further engineered to target specific cell types, and optionally to have altered/improved drug binding characteristics. These fusion proteins are useful in, for example, delivery of chemotherapeutic compounds to cancer cells.

Abstract: The present invention provides library of glutarimide-containing polyketide analogs, such as analogs of migrastatin, iso-migrastatin, dorrigocin A and B, epi-dorrigocin, NK30424 A and B and lactimidomycin, methods of synthesizing and using these analogs and further methods of creating a combinatorial library of these compounds through chemical modifications.

Abstract: This invention provides nucleic acid sequences and characterization of the gene cluster responsible for the biosynthesis of the enediyne C-1027 (produced by Streptomyces globisporus). The pathway comprises a nonriobsomal peptide synthetase (NRPS). Methods are provided for the biosynthesis of enediynes, enediyne analogs and other biological molecules.